Research programme: epilepsy therapeutics - Bicoll GmbH/InteRNA Technologies
Latest Information Update: 14 Nov 2013
At a glance
- Originator Bicoll GmbH; InteRNA Technologies
- Class Small molecules
- Mechanism of Action MicroRNA modulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Research Epilepsy
Most Recent Events
- 18 Sep 2013 Early research in Epilepsy in European Union (unspecified route)